703 related articles for article (PubMed ID: 31353502)
21. 4-1BB Agonism Combined With PD-L1 Blockade Increases the Number of Tissue-Resident CD8+ T Cells and Facilitates Tumor Abrogation.
Qu QX; Zhu XY; Du WW; Wang HB; Shen Y; Zhu YB; Chen C
Front Immunol; 2020; 11():577. PubMed ID: 32391001
[TBL] [Abstract][Full Text] [Related]
22. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes.
Kang HJ; Oh JH; Chun SM; Kim D; Ryu YM; Hwang HS; Kim SY; An J; Cho EJ; Lee H; Shim JH; Sung CO; Yu E
J Hepatol; 2019 Jul; 71(1):91-103. PubMed ID: 30930222
[TBL] [Abstract][Full Text] [Related]
23. Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma.
Di Blasi D; Boldanova T; Mori L; Terracciano L; Heim MH; De Libero G
Cell Mol Gastroenterol Hepatol; 2020; 9(2):195-218. PubMed ID: 31445190
[TBL] [Abstract][Full Text] [Related]
24. Enhanced Phenotype Definition for Precision Isolation of Precursor Exhausted Tumor-Infiltrating CD8 T Cells.
Martinez-Usatorre A; Carmona SJ; Godfroid C; Yacoub Maroun C; Labiano S; Romero P
Front Immunol; 2020; 11():340. PubMed ID: 32174925
[TBL] [Abstract][Full Text] [Related]
25. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
[TBL] [Abstract][Full Text] [Related]
26. CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor.
Ye Q; Song DG; Poussin M; Yamamoto T; Best A; Li C; Coukos G; Powell DJ
Clin Cancer Res; 2014 Jan; 20(1):44-55. PubMed ID: 24045181
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
28. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
29. 14-3-3ζ delivered by hepatocellular carcinoma-derived exosomes impaired anti-tumor function of tumor-infiltrating T lymphocytes.
Wang X; Shen H; Zhangyuan G; Huang R; Zhang W; He Q; Jin K; Zhuo H; Zhang Z; Wang J; Sun B; Lu X
Cell Death Dis; 2018 Feb; 9(2):159. PubMed ID: 29415983
[TBL] [Abstract][Full Text] [Related]
30. The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment.
Williams JB; Horton BL; Zheng Y; Duan Y; Powell JD; Gajewski TF
J Exp Med; 2017 Feb; 214(2):381-400. PubMed ID: 28115575
[TBL] [Abstract][Full Text] [Related]
31. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8
Zhang H; Zhang Y; Dong J; Zuo S; Meng G; Wu J; Wei J
Cell Oncol (Dordr); 2021 Dec; 44(6):1243-1255. PubMed ID: 34491549
[TBL] [Abstract][Full Text] [Related]
32. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
33. Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Buchan SL; Dou L; Remer M; Booth SG; Dunn SN; Lai C; Semmrich M; Teige I; Mårtensson L; Penfold CA; Chan HTC; Willoughby JE; Mockridge CI; Dahal LN; Cleary KLS; James S; Rogel A; Kannisto P; Jernetz M; Williams EL; Healy E; Verbeek JS; Johnson PWM; Frendéus B; Cragg MS; Glennie MJ; Gray JC; Al-Shamkhani A; Beers SA
Immunity; 2018 Nov; 49(5):958-970.e7. PubMed ID: 30446386
[TBL] [Abstract][Full Text] [Related]
34. Intratumoral Activation of 41BB Costimulatory Signals Enhances CD8 T Cell Expansion and Modulates Tumor-Infiltrating Myeloid Cells.
Innamarato P; Asby S; Morse J; Mackay A; Hall M; Kidd S; Nagle L; Sarnaik AA; Pilon-Thomas S
J Immunol; 2020 Nov; 205(10):2893-2904. PubMed ID: 33020146
[TBL] [Abstract][Full Text] [Related]
35. VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.
Zhang M; Pang HJ; Zhao W; Li YF; Yan LX; Dong ZY; He XF
BMC Cancer; 2018 May; 18(1):511. PubMed ID: 29720116
[TBL] [Abstract][Full Text] [Related]
36. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model.
Chen S; Lee LF; Fisher TS; Jessen B; Elliott M; Evering W; Logronio K; Tu GH; Tsaparikos K; Li X; Wang H; Ying C; Xiong M; VanArsdale T; Lin JC
Cancer Immunol Res; 2015 Feb; 3(2):149-60. PubMed ID: 25387892
[TBL] [Abstract][Full Text] [Related]
37. PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Gros A; Robbins PF; Yao X; Li YF; Turcotte S; Tran E; Wunderlich JR; Mixon A; Farid S; Dudley ME; Hanada K; Almeida JR; Darko S; Douek DC; Yang JC; Rosenberg SA
J Clin Invest; 2014 May; 124(5):2246-59. PubMed ID: 24667641
[TBL] [Abstract][Full Text] [Related]
38. PD-1 blockade restores helper activity of tumor-infiltrating, exhausted PD-1hiCD39+ CD4 T cells.
Balança CC; Salvioni A; Scarlata CM; Michelas M; Martinez-Gomez C; Gomez-Roca C; Sarradin V; Tosolini M; Valle C; Pont F; Ferron G; Gladieff L; Vergez S; Dupret-Bories A; Mery E; Rochaix P; Fournié JJ; Delord JP; Devaud C; Martinez A; Ayyoub M
JCI Insight; 2021 Jan; 6(2):. PubMed ID: 33332284
[TBL] [Abstract][Full Text] [Related]
39. PD-1
Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
[No Abstract] [Full Text] [Related]
40. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer.
Ostroumov D; Duong S; Wingerath J; Woller N; Manns MP; Timrott K; Kleine M; Ramackers W; Roessler S; Nahnsen S; Czemmel S; Dittrich-Breiholz O; Eggert T; Kühnel F; Wirth TC
Hepatology; 2021 Apr; 73(4):1399-1418. PubMed ID: 32716559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
